All In Biotech

NDA 010596 · Parke Davis

Celontin

Methsuximide · Oral · Anti-epileptic Agent

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 15, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1957

Feb 8, 1957

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

182

107 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

INDICATIONS AND USAGE Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 8, 1957 Original approval · Type 1 - New Molecular Entity · priority review Medication Guide
2 products under this application
  • CELONTIN · METHSUXIMIDE 150MG · CAPSULE, ORAL · Discontinued
  • CELONTIN · METHSUXIMIDE 300MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methsuximide" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective25
  • seizure21
  • convulsion14
  • dizziness13
  • somnolence13
  • feeling abnormal11
  • generalised tonic-clonic seizure11
  • off label use11
  • fall9
  • asthenia8
  • drug interaction8
  • fatigue8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20053
20062
20072
20093
20107
20112
20129
20136
20146
201513
201610
20177
201821
201915
202015
202114
202214
20236
20249
20256
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Celontin (Methsuximide)

2024 spending

$249K

Beneficiaries

110

587 claims

Per beneficiary

$2,260

$4.50 per unit

View as table
YearSpending
2020$1,186,246
2021$1,007,695
2022$885,860
2023$695,875
2024$248,624

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.